Concepedia

Janusz Mezynski

JM

Statistics

Publications

3

Citations

295

H-Index

3

Active since

2012

Affiliations

Institute of Cancer Research(Current)

Janusz Mezynski is an author at Institute of Cancer Research specializing in pharmacotherapy, medicine, and pharmacology.

Top concepts

Publications per year

2012–2018

3

Publications

3

Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?

Janusz Mezynski, Carmel Pezaro, Diletta Bianchini et al. · Annals of Oncology · 2012 · 246 citations

, , +7

A phase I dose escalation study of oral MK-2206 (allosteric Akt inhibitor) with oral selumetinib (AZD6244; ARRY-142866) (MEK 1/2 inhibitor) in patients with advanced or metastatic solid tumors.

Khurum Khan, Li Yan, Janusz Mezynski et al. · Journal of Clinical Oncology · 2012 · 36 citations

, , +13

Frequency, impact and a preclinical study of novel <i>ERBB</i> gene family mutations in HER2-positive breast cancer

Naomi Elster, Sinéad Toomey, Yue Fan et al. · Therapeutic Advances in Medical Oncology · 2018 · 13 citations · Full text

Rows per page

1–3 of 3